Glaucoma Clinical Trials

Find Glaucoma Clinical Trials Near You

A Cross-Sectional, Prospective Observational Study on the Role of the Vitreous Zonule in the Pathogenesis of Primary Angle-Closure Glaucoma

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This study aims to investigate the role of the vitreous zonule (VZ) in the pathogenesis of primary angle-closure glaucoma (PACG) and to explore the feasibility of three-dimensional ultrasound biomicroscopy (3D-UBM) for imaging the circumferential VZ. This prospective, observational study will enroll patients with primary angle-closure disease (PACD), including primary angle-closure suspect (PACS), primary angle-closure (PAC), and PACG, as well as healthy controls. All participants will undergo comprehensive ophthalmic examinations, including gonioscopy, biometric measurements using IOLMaster, and UBM imaging. The study consists of three main components: (1) analysis of VZ morphology, location, number of visible quadrants, and anterior segment parameters across different age groups and axial length groups in healthy individuals, with comparisons to age-matched PACD patients; (2) development and validation of a 3D-UBM imaging system using a rotational scanning approach to reconstruct the spatial structure of the VZ; and (3) characterization of VZ features, including density and morphology, in normal eyes versus PACD eyes using 3D-UBM. The primary outcomes include the presence, quadrant count, and morphological characteristics (vitreous zonule-pars plana angle and maximum distance) of the VZ, as well as anterior segment parameters such as lens vault, anterior chamber depth, trabecular-iris angle, and angle opening distance. By elucidating age-related and axial length-related changes in the VZ and establishing 3D-UBM as a novel imaging modality for the posterior zonular apparatus, this study seeks to provide new evidence for the mechanistic role of the VZ in angle-closure glaucoma and to identify potential imaging biomarkers for early diagnosis and risk stratification.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 79
Healthy Volunteers: t
View:

• 1\. Age between 30 and 80 years, inclusive. 2. Diagnosis of primary angle-closure disease (PACS, PAC, or PACG) according to standardized gonioscopic criteria; or healthy controls with open angles. 3. Lens opacity graded \< 2 for cortical and nuclear opacities according to the Lens Opacities Classification System III (LOCS III). 4. Ability and willingness to provide written informed consent.

Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
Kun Lv, M.D.
lvkun0327@163.com
13681213130
Time Frame
Start Date: 2025-01-01
Estimated Completion Date: 2027-06
Participants
Target number of participants: 440
Treatments
Group 1 Healthy Controls
Group 2 Primary Angle-Closure Suspects (PACS)
Group 3 Primary Angle Closure
Group 4 Primary Angle Closure Glaucoma
Related Therapeutic Areas
Sponsors
Leads: Peking University People's Hospital

This content was sourced from clinicaltrials.gov